{"id":15605,"date":"2021-01-05T01:24:02","date_gmt":"2021-01-04T22:24:02","guid":{"rendered":"https:\/\/www.klimikdergisi.org\/\/2021\/01\/05\/farkli-pegile-interferon-molekulleriyle-ribavirin-kombinasyonlarinin-hematolojik-yan-etkiler-acisindan-karsilastirilmasi\/"},"modified":"2021-01-05T01:24:02","modified_gmt":"2021-01-04T22:24:02","slug":"farkli-pegile-interferon-molekulleriyle-ribavirin-kombinasyonlarinin-hematolojik-yan-etkiler-acisindan-karsilastirilmasi","status":"publish","type":"post","link":"https:\/\/www.klimikdergisi.org\/tr\/2021\/01\/05\/farkli-pegile-interferon-molekulleriyle-ribavirin-kombinasyonlarinin-hematolojik-yan-etkiler-acisindan-karsilastirilmasi\/","title":{"rendered":"Farkl\u0131 Pegile \u0130nterferon-&#945; Molek\u00fclleriyle Ribavirin Kombinasyonlar\u0131n\u0131n Hematolojik Yan Etkiler A\u00e7\u0131s\u0131ndan Kar\u015f\u0131la\u015ft\u0131r\u0131lmas\u0131"},"content":{"rendered":"<h1>\u00d6zet<\/h1>\n<p> <strong>Ama\u00e7<\/strong>: Kronik hepatit C virusu (HCV) infeksiyonunun pegile interferon (PegIFN) ve ribavirinle tedavisi, anemi, l\u00f6kopeni ve trombositopeni gibi hematolojik yan etkilere yol a\u00e7abilmektedir. Bu \u00e7al\u0131\u015fmada, kronik HCV tedavisinde ribavirinle birlikte kullan\u0131lan PegIFN \u03b1-2a ile PEGIFN \u03b1-2b\u2019nin hematolojik yan etkilerinin kar\u015f\u0131la\u015ft\u0131r\u0131lmas\u0131 ama\u00e7land\u0131.<\/p>\n<p> <strong>Y\u00f6ntemler<\/strong>: Bu retrospektif \u00e7al\u0131\u015fmaya PegIFN \u03b1-2b ve ribavirin tedavisi alan 103 hastayla PegIFN \u03b1-2a ve ribavirin tedavisi alan 70 hasta dahil edildi. Tedavinin birinci ve \u00fc\u00e7\u00fcnc\u00fc aylar\u0131nda yap\u0131lan kontrollerdeki hematolojik parametreler tedavi \u00f6ncesi de\u011ferleriyle kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131.<\/p>\n<p> <strong>Bulgular<\/strong>: \u00dc\u00e7\u00fcnc\u00fc ay\u0131n sonunda t\u00fcm hastalar\u0131n %21.2\u2019sinde anemi (hemoglobin &lt;10 gr\/dl), %3.8\u2019inde n\u00f6tropeni (&lt;750\/mm3) ve %6.2\u2019sinde trombositopeni (&lt;75&#215;109\/lt) saptand\u0131. Her iki grupta da tedavinin birinci ve \u00fc\u00e7\u00fcnc\u00fc aylar\u0131nda hemoglobin, n\u00f6trofil ve trombosit de\u011ferlerinde ba\u015flang\u0131\u00e7la kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda anlaml\u0131 azalma saptand\u0131. Birinci ay\u0131n sonunda saptanan trombosit de\u011ferlerindeki azalma iki grup aras\u0131nda farkl\u0131 bulunmazken, \u00fc\u00e7\u00fcnc\u00fc ayda PegIFN \u03b1-2a ve ribavirin alanlarda PegIFN \u03b1-2b ve ribavirin alanlara g\u00f6re anlaml\u0131 olarak daha fazla bulundu.<\/p>\n<p> <strong>Sonu\u00e7lar<\/strong>: PegIFN \u03b1-2a ile PegIFN \u03b1-2b kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda, trombosit say\u0131lar\u0131 \u00fczerine olan etkilerinin d\u0131\u015f\u0131nda benzer hematolojik yan etkilere sahip olduklar\u0131 g\u00f6zlenmi\u015ftir.\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00d6zet Ama\u00e7: Kronik hepatit C virusu (HCV) infeksiyonunun pegile interferon (PegIFN) ve ribavirinle tedavisi, anemi, l\u00f6kopeni ve trombositopeni gibi hematolojik yan etkilere yol a\u00e7abilmektedir. Bu \u00e7al\u0131\u015fmada, kronik HCV tedavisinde ribavirinle birlikte kullan\u0131lan PegIFN \u03b1-2a ile PEGIFN \u03b1-2b\u2019nin hematolojik yan etkilerinin kar\u015f\u0131la\u015ft\u0131r\u0131lmas\u0131 ama\u00e7land\u0131. Y\u00f6ntemler: Bu retrospektif \u00e7al\u0131\u015fmaya PegIFN \u03b1-2b ve ribavirin tedavisi alan 103 hastayla PegIFN [&hellip;]<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[5129],"tags":[2587,4406,4408,3874],"class_list":["post-15605","post","type-post","status-publish","format-standard","hentry","category-ozgun-arastirma","tag-hepatit-c","tag-pegile-interferon-2a","tag-pegile-interferon-2b","tag-ribavirin"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/posts\/15605","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/comments?post=15605"}],"version-history":[{"count":0,"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/posts\/15605\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/media?parent=15605"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/categories?post=15605"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/tags?post=15605"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}